A RANDOMIZED, OPEN-LABEL, PHASE 2 STUDY OF BORTEZOMIB AND DEXAMETHASONE WITH OR WITHOUT ELOTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

被引：0

作者：

Jakubowiak, A. ^{[1
]}

Offidani, M. ^{[2
]}

Pegourie, B. ^{[3
]}

De La Rubia, J. ^{[4
]}

Garderet, L. ^{[5
]}

Laribi, K. ^{[6
]}

Bosi, A. ^{[7
]}

Marasca, R. ^{[8
]}

Laubach, J. ^{[9
]}

Mohrbacher, A. ^{[10
]}

Carella, A. M. ^{[11
]}

Singhal, A. K. ^{[12
]}

Tsao, L. C. ^{[12
]}

Lynch, M. ^{[13
]}

Bleickardt, E. ^{[13
]}

Jou, Y. M. ^{[13
]}

Palumbo, A. ^{[14
]}

机构：

[1] Univ Chicago, Med Ctr, Chicago, IL 60637 USA

[2] Osped Riuniti Ancona, Azienda Osped Univ, Ancona, Italy

[3] Hop Albert Michallon, CHU Grenoble, Grenoble, France

[4] HUP La Fe, Valencia, Spain

[5] Hop St Antoine, F-75571 Paris, France

[6] Ctr Hosp, Le Mans, France

[7] Azienda Osped Univ Careggi, Florence, Italy

[8] Azienda Osped Univ, Policlin Modena, Modena, Italy

[9] Dana Farber Canc Inst, Boston, MA 02115 USA

[10] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA

[11] IRCCS San Martino IST, Genoa, Italy

[12] AbbVie Biotherapeut Inc ABR, Redwood City, CA USA

[13] Bristol Myers Squibb Co, Wallingford, CT 06492 USA

[14] Osped Molinette, Azienda Osped Univ San Giovanni Battista Torino, Turin, Italy

来源：

HAEMATOLOGICA | 2015年 / 100卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

S103

引用

页码：2 / 2

页数：1

共 50 条

[1] ELOQUENT-2: A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF LENALIDOMIDE/DEXAMETHASONE WITH OR WITHOUT ELOTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
Dimopoulos, M.
Lonial, S.
Palumbo, A.
White, D.
Grosicki, S.
Spicka, I.
Walter-Croneck, A.
Moreau, P.
Mateos, M. -V.
Magen, H.
Belch, A.
Reece, D.
Beksac, M.
Spencer, A.
Oakervee, H.
Taniwaki, M.
Roellig, C.
Wu, K. L.
Singhal, A.
San Miguel, J.
Matsumoto, M.
Katz, J.
Bleickardt, E.
Poulart, V.
Richardson, P.
HAEMATOLOGICA, 2015, 100 : 173 - 173
[2] Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma
Jacob P. Laubach
Sascha A. Tuchman
Jacalyn M. Rosenblatt
Constantine S. Mitsiades
Kathleen Colson
Kelly Masone
Diane Warren
Robert A. Redd
Dena Grayson
Paul G. Richardson
Blood Cancer Journal, 11
[3] A Phase 3 randomized, open-label trial of selinexor, pomalidomide, and dexamethasone versus elotuzumab, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma
Weisel, Katja
Bentur, Ohad
Van Domelen, Dane
Boccadoro, Mario
Sonneveld, Pieter
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S216 - S217
[4] A randomized phase 2 study of pomalidomide/dexamethasone with or without elotuzumab in patients with relapsed/refractory multiple myeloma.
San Miguel, Jesus
Raab, Marc S.
Goldschmidt, Hartmut
Lonial, Sagar
Richardson, Paul G.
Shelat, Suresh
Bleickardt, Eric W.
Palumbo, Antonio
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[5] Phase 1 open-label study of panobinostat, lenalidomide, bortezomib plus dexamethasone in relapsed and relapsed/refractory multiple myeloma
Laubach, Jacob P.
Tuchman, Sascha A.
Rosenblatt, Jacalyn M.
Mitsiades, Constantine S.
Colson, Kathleen
Masone, Kelly
Warren, Diane
Redd, Robert A.
Grayson, Dena
Richardson, Paul G.
BLOOD CANCER JOURNAL, 2021, 11 (02)
[6] A phase 3 randomized, controlled, open-label study of selinexor, bortezomib, and dexamethasone (SVd) versus bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma (RRMM).
Delimpasi, Sosana
Pour, Ludek
Auner, Holger W.
Dimopoulos, Meletios A.
Rappaport, Alon
Fortin, Lisa
Shah, Jatin J.
Shacham, Sharon
Kauffman, Michael G.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[7] ELOQUENT-2: A phase III, randomized, open-label study of lenalidomide (Len)/dexamethasone (dex) with/without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
Lonial, Sagar
Dimopoulos, Meletios A.
Palumbo, Antonio
White, Darrell
Grosicki, Sebastian
Spicka, Ivan
Walter-Croneck, Adam
Moreau, Philippe
Mateos, Maria-Victoria
Magen-Nativ, Hila
Belch, Andrew
Reece, Donna Ellen
Beksac, Meral
Taniwaki, Masafumi
Roellig, Christoph
Singhal, Anil K.
Katz, Jessica
Bleickardt, Eric W.
Poulart, Valerie
Richardson, Paul G.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[8] CheckMate 602: A Phase 3, Open-Label, Randomized Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide, and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma
Lonial, Sagar
Richardson, Paul
Reece, Donna
Mohamed, Hesham
Shelat, Suresh
San Miguel, Jesus
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S330 - S330
[9] A randomized phase II study of bortezomib (Btz)/dexamethasone (dex) with or without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
Jakubowiak, Andrzej J.
Offidani, Massimo
Pegourie, Brigitte
De La Rubia, Javier
Garderet, Laurent
Laribi, Kamel
Bosi, Alberto
Marasca, Roberto
Laubach, Jacob
Mohrbacher, Ann
Carella, Angelo Michele
Singhal, Anil K.
Tsao, Claire
Lynch, Mark John
Bleickardt, Eric W.
Jou, Ying-Ming
Palumbo, Antonio
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[10] Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
Dimopoulos, Meletios A.
Moreau, Philippe
Palumbo, Antonio
Joshua, Douglas
Pour, Ludek
Hajek, Roman
Facon, Thierry
Ludwig, Heinz
Oriol, Albert
Goldschmidt, Hartmut
Rosinol, Laura
Straub, Jan
Suvorov, Aleksandr
Araujo, Carla
Rimashevskaya, Elena
Pika, Tomas
Gaidano, Gianluca
Weisel, Katja
Goranova-Marinova, Vesselina
Schwarer, Anthony
Minuk, Leonard
Masszi, Tamas
Karamanesht, Ievgenii
Offidani, Massimo
Hungria, Vania
Spencer, Andrew
Orlowski, Robert Z.
Gillenwater, Heidi H.
Mohamed, Nehal
Feng, Shibao
Chng, Wee-Joo
LANCET ONCOLOGY, 2016, 17 (01): : 27 - 38

← 1 2 3 4 5 →